Loading...
Enzon Pharmaceuticals, Inc.
ENZN•PNK
HealthcareBiotechnology
$0.09
$0.001(0.83%)
Enzon Pharmaceuticals, Inc. (ENZN) Stock Overview
Explore Enzon Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.00
↑ 693.88%
EPS Growth
$-0.00
↓ 869.23%
Operating Margin
-3850.00%
↓ 27.11%
ROE
-0.49%
↑ 693.88%
Dividend Yield
0.00%
↑ 0.04%
Analyst Recommendations data is not available for ENZNAnalyst Recommendations details for ENZN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
CEO
Mr. Richard L. Feinstein CPA
Headquarters
20 Commerce Drive, Cranford, NJ
Founded
1984